cyrilzakka/clinical-trials huggingface dataset:
Multicenter Validation of the Salivary miRNA Signature of Endometriosis

ENDOmiARN Salive Test is a multicentre external validation study of a salivary signature of endometriosis carried out in France in Obstetrics and Reproductive Medicine departments, in order to evaluate its performance and discuss its use in clinical practice. The clinical application is to significantly reduce the time to diagnosis and improve the care pathway for endometriosis.

The study population is made up of women aged 18 to 43 years with formally diagnosed endometriosis or suspected endometriosis who are already receiving either medical (MAP) or surgical treatment as part of their routine care.

The patients concerned by the study are managed without any change in the care pathway, nor any change in the therapeutic indications, nor any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the HAS recommendations.

In this study, the management and follow-up of patients :

* Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits,
* Are not modified in comparison with the usual follow-up, except for the performance of :

  * Collection of saliva
  * Electronic collection of the answers to the questionnaires completed by the patient


Eligibility Criteria:
Inclusion Criteria:

* Patient aged between 18 and 43 years,
* Patient having dated and signed the consent form,
* Patient affiliated to the French health system,
* Patient with pelvic MRI and/or pelvic ultrasound,
* Patient from one of the 3 study populations:

  * Patient with a formal endometriosis diagnosed by clinical examination and imaging AND an indication for specialised endometriosis follow-up or medically assisted procreation (MAP) or surgery validated by RCP (in routine care);
  * Patient with suspected endometriosis for whom the diagnosis is the source of a discrepancy between clinical and radiological data AND a surgical indication validated by RCP (in routine care);
  * Patient with a gynaecological indication for surgery of the small pelvis by laparoscopy or laparoscopy validated in RCP (in routine care) AND symptoms suggestive of endometriosis (dysmenorrhoea, ....)(1).

Exclusion Criteria:

* Patient with recurrence of deep endometriosis (excluding endometrioma),
* Patient with endometriosis of the torus and/or utero-sacral ligaments without indication for surgery,
* Patient with parietal endometriosis alone without indication for surgery,
* Patient with adenomyosis alone on imaging without indication for surgery,
* Patient with gynaecological infection requiring surgical management,
* Pregnant patient,
* Patient infected with the human immunodeficiency virus (HIV),
* Patient with significant difficulties in reading or writing the French language,
* Patient with a personal history of cancer,
* Patient unable to comply with study and/or follow-up procedures,
* Patient who has objected to the collection of her data.
* Patient participating in another clinical research study.
Correlation of Pelvic Asymmetry and Joint Movement During Gait in Children With Cerebral Palsy

the study's particular goals were to determine whether excessive hip, knee, and ankle displacement at first contact during locomotion correlates with pelvic rotation.


Eligibility Criteria:
Inclusion Criteria:

* the lower extremities' degree of spasticity ranged from grade 1 to grade +1 on the Gross Motor Function Classification System (GMFCS) \[7\] classified motor function levels as being between levels I and II. Children have the cognitive ability to understand and follow instructions.

Exclusion Criteria:

* having an extensive intellectual disability, orthopedic issues, upper or lower limb surgery, visual or hearing issues, usage of behavior-altering medicines, or a major neurological illness (epilepsy)
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18
* Hospitalized for peritoneal catheter placement for peritoneal dialysis

Exclusion Criteria:

* Pregnancy
* Hiperkalemia (K\> 5.5meq/l)
* Intolerance to spironolactone
Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)

The aim of the study is the evaluation of the efficiency and safety of the new, CE-certified thermofu-sion and dissection instrument BiCision® in comparison with the long established Ultracision® Har-monic Scalpel(Ethicon)during a laparoscopic supracervical hysterectomy (LASH).


Eligibility Criteria:
Inclusion Criteria:

* age \> 18
* gender: female
* indication for laparoscopic supracervical hysterectomy with no adnexectomyor other surgery
* will and the capability to comply the study requirements
* signed informed consent

Exclusion Criteria:

* Invasive malignome in the pelvis
* Cardiac pacemaker or implanted defibrilator if no informations are available about the compatibil-ity with RF energy
* Abnormal blood parameters (values less than factor 0.8 or more than 1.25 compared to the val-ues of creatinine and standard hemogram)
* Abnormal coagulation parameters: PTT \> 40 sec. and / or Quick's-Value\< 50% (the use of antiplateletsup to a max. of 100mg/d is no exclusion criteria)
* Inability to understand the purpose of the study
* status after a laparotomy by a longitudinal incision
* intraabdominal adhesions (at the beginning of the surgery ≥ 5 sectioning for adhesiolysis)
* open laparoscopy required
* different anatomical situations that yields to different surgery requirements
* conspicuous PAP, cervixmyoma or endometriosis of the rectovaginale space
Brown Rice Intervention on Metabolic Syndrome (BRIMS)

The specific aim of this study is to determine the effects of substituting brown for white rice on the treatment of metabolic syndrome (MetS).

Metabolic syndrome (MetS), a constellation of metabolic abnormalities including central obesity, dyslipidemia, elevated blood pressure and hyperglycemia, is associated with the development of type 2 diabetes and CVD. It has become one of the major public health challenges in China due to rapidly nutrition transition and the nature of obesity epidemic. Treatment of MetS in China is very important for the prevention of the epidemic of its consequences (such as CVD and type 2 diabetes).

Compelling evidence from recent human studies has demonstrated that diet modifications are effective means in MetS management. Consumption of carbohydrate-rich foods such as rice affects blood glucose and influences diabetes risk. Specifically, eating polished white rice may increase diabetes risk, whereas eating brown rice, a whole grain product, may decrease risk. This is likely related to the different ability of white and brown rice to raise blood glucose levels, as measured by their glycemic index (GI) and glycemic load (GL), and to the higher levels of dietary fiber, vitamin B complex, magnesium and other micronutrients in brown rice.

A total of 200 participants with MetS (defined by ATP-III criteria) will be randomly assigned to a brown rice diet or an isocaloric white rice diet for 16 weeks. Effects of substituting brown for white rice will be evaluated by measuring metabolic profile (BMI, blood pressure, total cholesterol, triglyceride, LDL-C and HDL-C, fasting glucose and insulin, HbA1C).

Eligibility Criteria:
Inclusion Criteria:

* The updated National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for the diagnosis of the MetS will be used. MetS will be defined with at least three of the following abnormalities:

  * central obesity (defined as waist circumference ≥ 80 cm for women or ≥ 90 cm for men)
  * Raised triglycerides level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality;
  * Reduced HDL cholesterol: \< 40 mg/dL (1.0 mmol/L) in males and \< 50 mg/dL (1.3 mmol/L) in females, or specific treatment for this lipid abnormality;
  * Elevated blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension;
  * Increased fasting plasma glucose (FPG): ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes.
* Being able to comply with the specified feeding conditions
* Being able to eat brown rice
* Being between the ages of 35 and 60 years

Exclusion Criteria:

* Pregnancy or lactation
* Use of insulin
* Severe kidney disease
* Cardiovascular diseases, stroke, cancer and psychological disorders
* Brown rice allergies
* Drug or alcohol abuse
Turkish Validity and Reliability Study of the "Sexual Health Care Questionnaire"

Determining the knowledge, attitudes and self-efficacy of nursing students in the field of sexual health care is important for the development and planning of nursing education and research. There is no Turkish tool in the literature that will enable a comprehensive assessment of nursing students' knowledge, attitudes and self-efficacy towards sexual health care. The aim of the study is to determine the validity and reliability of the Turkish version of the three scales (knowledge, attitude, self-efficacy) in the "Sexual Healthcare Questionnaire" for nursing students. This is a methodological study. These scales translated into Turkish language. Data will be collected in April 2023 through an online questionnaire from nursing students at a public university in Turkey. The test-retest will be performed again after 4 weeks. At least 310 participants from 2nd and 3rd year nursing students will be included in the study.

Sexuality is an indispensable part of being human, affecting the lives of individuals. It is necessary to provide sexual health services to support the quality of life of individuals who have problems with sexual health. In addition to being in a unique position in the field of practice to provide sexual health care, nurses' service on sexual issues is an important professional responsibility in order to provide holistic care. Determining the knowledge, attitudes and self-efficacy of nursing students in the field of sexual health care is important for the development and planning of nursing education and research. There is no Turkish tool in the literature that will enable a comprehensive assessment of nursing students' knowledge, attitudes and self-efficacy towards sexual health care. The aim of the study is to determine the validity and reliability of the Turkish version of the three scales (knowledge, attitude, self-efficacy) in the "Sexual Healthcare Questionnaire" for nursing students. This is a methodological study. These scales translated into Turkish language. Data will be collected in April 2023 through an online questionnaire from nursing students at a public university in Turkey. The test-retest will be performed again after 4 weeks. At least 310 participants from 2nd and 3rd year nursing students will be included in the study.

Eligibility Criteria:
Inclusion Criteria:

* Being a 2nd or 3rd year nursing student
* Absence of psychiatric illness
* Being willing to participate

Exclusion Criteria:

* Desire to leave the research
Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions

Patient decision aids are tools that help guide individuals through a healthcare-related decision making process. They help users combine evidence-based information and recommendations by a health care provider with their personal needs, values and preferences. Through this project, Dr. Dobbins and her research team will explore whether the use of patient decision aids with high-quality and user-friendly summaries of research evidence, or summaries of research evidence alone, help to improve the quality of decision making by men facing prostate cancer screening decisions.

Guidelines for prostate screening in Canada are based on low-moderate quality evidence of effectiveness and screening is associated with potential harms. Patient Decision Aids (PDAs) are tools that assist users to understand treatment options, risks and benefits to align decisions with values and preferences. The investigators would now like to know whether use of a PDA alongside evidence-based information provided through the McMaster Optimal Aging Portal, or simply access to evidence-based information alone, can help users to make informed decisions about prostate cancer screening in men.

Eligibility Criteria:
Inclusion Criteria:

* English speaking men, \> 50 years old

Exclusion Criteria:

* History of prostate cancer or PSA test in the last 12 months
Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples

This study utilizes a randomized controlled trial design to evaluate the efficacy of two intervention components for couples HIV testing and counseling (CHTC): a communication skills training video and a substance use module. Participants are randomized in a full-factorial design to one of 4 conditions: CHTC as usual; CHTC + communication skills training videos; CHTC + substance use module; or CHTC plus both adjunct components.


Eligibility Criteria:
Inclusion Criteria:

* · Have a main partner who is another male and have been in a relationship for 3 month or longer

  * One participant must be between 17 and 29; Main partner can be any age above 17.
  * One participant must be HIV negative (as confirmed by rapid test)
  * One participant must have used at least 1 drug in the past 90 days (cocaine/crack, opiates, misuse of prescription medication, stimulants, psychedelics, ecstasy, ketamine, GHB)
  * One participant must have engaged in Transmission Risk Behavior (TRB) in the past 90 days

    o Defined as Condom-less Anal Sex (CAS) with a casual partner and/or CAS with a non-monogamous or serodiscordant main partner
  * Live in the NYC or Detroit metropolitan area
  * Speak English

Exclusion Criteria:

* · Any signs of serious mental illness or cognitive deficit

  * History of IPV with their main partner and safety concerns in the current relationship.
Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy

Background : When a mother contracts toxoplasmosis during pregnancy, the parasite may be transmitted from to her unborn child. This results in congenital toxoplasmosis, which may cause damage to the eyes and nervous system of the child. To date, no method has been proved effective to prevent this transmission. In France, spiramycin is usually prescribed to women who have toxoplasma seroconversion in pregnancy, however its efficacy has not been determined. The standard treatment for toxoplasmosis is the combination of the antiparasitic drugs pyrimethamine and sulfadiazine, but this strategy has not been evaluated for the prevention of mother-to-child transmission.

Purpose : Randomized phase 3 trial to determine whether pyrimethamine + sulfadiazine is more effective than spiramycin to prevent congenital toxoplasmosis.

The protocol is a comparison of 2 strategies to prevent mother-to-child transmission of T. gondii following maternal seroconversion.

Screening for toxoplasmosis is mandatory in France. Patients with confirmed seroconversion will be eligible for the trial, after 14 weeks gestational age.

Participants will be randomly allocated to one of the treatment groups, and will receive open-label pyrimethamine + sulfadiazine or spiramycin.

The protocol will not change the usual procedures for prenatal diagnosis, nor will it change the management of infected fetuses and neonates.

Eligibility Criteria:
Inclusion Criteria:

* \> 18 years old
* Toxoplasmosis infection acquired during the pregnancy documented by at least one negative serology in the first trimester and seroconversion with presence of specific IgG antibodies
* Gestational age \> 14 weeks from last menstrual period
* Signature of informed consent

Exclusion Criteria:

* Lack of a documented negative serology during the pregnancy
* Antiparasitic therapy with spiramycin, pyrimethamine or sulfa drugs for more than 10 days after seroconversion and before randomization,
* Known allergy to any of the study drugs, serious allergic conditions or G6PD deficiency,
* Known hepatic or renal insufficiency,
* Other ongoing severe conditions in mother or fetus
* Lack of public health insurance
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.


Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent
* Age ≥ 18 years
* Patients with confirmed solid tumor and scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosage and schedule in the study.
* Experienced thrombocytopenia as evidenced by a platelet count \< 100 Gi/L in the preceding cycle immediately before study enrollment.
* ECOG performance status ≤ 2
* For females, surgically sterilized, postmenopausal or agree to use an acceptable form of birth control
* Patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib, trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by the investigator and after consultation and approval from the Sponsor
* PT/INR and aPTT are within 80% to 120% of the normal range

Exclusion Criteria:

* Experienced thrombocytopenia as evidenced by a platelet count \< 25 Gi/L at any time in the preceding cycle immediately before enrollment into the study
* History or presence of clinically significant disease
* Received any TRAs, or rHuIL-11 within the last 4 weeks prior to screening
* Had received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening).
* Pregnant, wanting to become pregnant or lactating
Pain Control in Elderly Hip Fracture Patients: Is Intravenous Acetaminophen Superior to Oral Administration?

The primary objective is to determine if intravenous acetaminophen decreases pain scores and the amount of morphine equivalence received as compared to oral acetaminophen in patients greater than 65 years old after sustaining a hip fracture.

Surgeons involved in this research agree to the randomization of patients into one of two groups. After informed consent, patients will be randomly assigned in a 1:1 ratio to the treatment group or the control group.

Group 1: This group will serve as the control group, and will be scheduled to receive one gram (1g) acetaminophen PO every 8 hours.

Group 2: This group will serve as the treatment group, and will be scheduled to receive one gram (1g) acetaminophen IV every 8 hours

The standardized pain control protocol for hip fracture patients will be initiated for all patients. The pain protocol will be initiated at hospital admission, and after three postoperative doses of the group assigned acetaminophen all patients will be switched to one gram scheduled acetaminophen PO in preparation for hospital discharge.

Eligibility Criteria:
Inclusion Criteria:

1. Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
2. Age ≥ 65 years.
3. Low energy mechanism.
4. Hip fracture fixation performed within 48 hours of injury.
5. English speaking.
6. Anticipated medical optimization for operative fixation.
7. No other major trauma.

Exclusion Criteria:

1. Unable to provide informed consent (dementia, limited decision making capacity)
2. Admitted by medical service for significant co-morbidities
3. Retained hardware around the affected hip
4. Infection around the affected hip
5. Transfer patients with a length of stay \> 24 hours at the transferring hospital
6. Known allergy to acetaminophen
7. Current use of narcotics
8. Receiving a regional anesthetic block at any point during the hospitalization
9. Known history of hepatic disease (hepatitis, cirrhosis)
10. Weight \< 50kg
11. Prisoner
12. Involved in another clinical trial that would interfere with the intervention of this study
Full-spectrum Endoscopy in Colorectal Cancer Screening

The purpose of this study is to compare the adenoma detection rates of full-spectrum endoscopy versus standard forward-viewing colonoscopy in colorectal cancer screening programme.

Colorectal cancer is the third most common neoplasia and the second leading cause of cancer death in West countries. Colonoscopy is the gold standard for prevention of colorectal cancer disease. Screening for colorectal cancer with biennial faecal occult blood testing is a widely used strategy followed by colonoscopy for those with a positive test. Colonoscopy identifies polyps during the procedure as well as polyp removal in order to prevent progression to cancer. Although, interval cancer appears after a colonoscopy because of 22-28% of polyp missed rates. Advanced Technology may improve adenoma detection rates so decrease interval cancer and reduce mortally. Full-spectrum endoscopy with 330º angle vision decrease adenoma miss rate in general population.

The investigators conducted a randomized trial in patients from colorectal cancer screening programme (aged 50-69 years) after faecal immunological test positive. One arm the colonoscopy is performed with standard forward view colonoscopy (170º angle view) and the other arm is performed with full-spectrum endoscopy (EndoChoice) (330º angle view)

Eligibility Criteria:
Inclusion Criteria:

* patient referred for colorectal cancer screening with positive fecal inmunological test.
* Age between 50 and 69 years

Exclusion Criteria:

* history of colonic resection,
* high risk for colorectal cancer like family history of colorectal cancer o polyposis syndrome,
* inflammatory bowel disease,
* patients with lower gastrointestinal bleeding symptoms,
* acute diverticulitis,
* colonic strictures,
* poor bowel preparation (Boston scale less than 5 points)